[et_pb_section fb_built=\u201d1\u2033 admin_label=\u201dsection\u201d _builder_version=\u201d4.16\u2033 custom_padding=\u201d0px||0px||true|false\u201d global_colors_info=\u201d{}\u201d][et_pb_row admin_label=\u201drow\u201d _builder_version=\u201d4.16\u2033 background_size =\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d width=\u201d100%\u201d custom_padding=\u201d0px||||\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033 custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_image src=\u201dhttps:\/\/oncogen.ro\/wp-content\/uploads\/2024\/01\/RDIA_group.jpg\u201d title_text=\u201dRDIA_group\u201d align=\u201dcenter \u201d force_fullwidth=\u201don\u201d _builder_version=\u201d4.24.2\u2033 _module_preset=\u201ddefault\u201d border_radii=\u201don|10px|10px|10px|10px\u201d global_colors_info=\u201d{}\u201d][\/et_pb_image][et_pb_text admin_label=\u201dText\u201d _builder_version =\u201d4.23.1\u2033 text_font_size=\u201d17px\u201d text_line_height=\u201d28px\u201d background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d]<\/p>\n
Immune T cells are the ones that normally recognize and destroy tumor cells, but during tumor progression, T cells begin to express the PD-1 receptor, which leads to the rapid exhaustion of the capacity of these cells. More recently, it has been found that information from dendritic cells, which collect data about malignant cells and present it to T cells, is vital for keeping T cells in an activated state. This finding explains why already existing therapeutic options based on anti-PD-1 antibodies have not been effective in cases where dendritic cells are missing around tumors.
Recently, a research group from the Weizmann Institute of Science (WIS) in Israel published in the prestigious journal "Cell" data about a new type of immunotherapy based on the interaction between T cells and dendritic cells, more precisely a new antibody was developed , called BiCE (Bispecific DC-T Cell Engager), which has the ability to connect T cells with dendritic cells, thus generating a strong immune response against cancer. This antibody binds and blocks on the one hand the PD-1 receptor that depletes the T cell, and on the other hand it binds the dendritic cell that brings the vital information to the T cell. The studies presented show that BiCE has shown efficacy in treating various types of cancer in mice, including breast, lung and skin cancer. What's more, this new antibody prevented the cancer from coming back, leaving behind memory immune cells capable of identifying and fighting the cancer.
The findings of the Israeli research team open new perspectives in immunotherapy, addressing a critical limitation of existing treatments related to the low presence of dendritic cells in most cancer tumors. This promising approach could revolutionize treatments for cancer and autoimmune diseases.<\/p>\n
The image taken from the article published by the research team shows how the BiCE antibody marked in yellow achieves the coupling between the T cell visualized in red and the dendritic cell in blue, thus achieving an association of these immune cells with increased and long-lasting effectiveness against tumor cells .<\/p>\n
[\/et_pb_text][et_pb_image src=\u201dhttps:\/\/oncogen.ro\/wp-content\/uploads\/2024\/01\/celule-T.jpg\u201d title_text=\u201dcelule T\u201d align=\u201dcenter\u201d _builder_version=\u201d4.23.1 \u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d{}\u201d][\/et_pb_image][et_pb_text admin_label=\u201dText\u201d _builder_version=\u201d4.23.1\u2033 text_font_size=\u201d17px\u201d text_line_height=\u201d28px\u201d background_size=\u201dinitial\u201d background_position=\u201dtop_left \u201d background_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d]<\/p>\n
Bispecific dendritic-T cell engager potentiates anti-tumor immunity<\/strong>. Yuval Shapir Itai<\/span>\u00a0<\/sup><\/span>,\u00a0<\/span>Oren Barboy<\/span>,\u00a0<\/span>Ran Salomon<\/span>\u00a0<\/sup><\/span>,\u00a0<\/span>Akhiad Berkovich<\/span>,\u00a0<\/span>Ken Xie<\/span>,\u00a0<\/span>Eitan Winter<\/span>,\u00a0<\/span>Tamar Shami<\/span>,\u00a0<\/span>Ziv Porat<\/span>\u00a0<\/sup><\/span>,\u00a0<\/span>Neta Erez<\/span>,\u00a0<\/span>Amos Tanay<\/span>,\u00a0<\/span>Ido Amit<\/span>,\u00a0<\/span>Rony Dahan. Cella<\/em>, 2024, <\/span>18;187(2):375-389.e18.<\/span> two: 10.1016\/j.cell.2023.12.011.<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":" Immune T cells are the ones that normally recognize and destroy tumor cells, but during tumor progression, T cells begin to express the PD-1 receptor, which leads to the rapid exhaustion of the capacity of these cells. More recently it has been found that information from dendritic cells, which collect data about malignant cells and [\u2026]<\/p>","protected":false},"author":2,"featured_media":101983,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[5,21],"tags":[],"class_list":["post-101978","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evenimente-stiintifice","category-stiri-oncogen"],"_links":{"self":[{"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/posts\/101978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/comments?post=101978"}],"version-history":[{"count":8,"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/posts\/101978\/revisions"}],"predecessor-version":[{"id":102029,"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/posts\/101978\/revisions\/102029"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/media\/101983"}],"wp:attachment":[{"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/media?parent=101978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/categories?post=101978"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/oncogen.ro\/en\/wp-json\/wp\/v2\/tags?post=101978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}